RU2633057C2 - Система и способ многофазного высвобождения факторов роста - Google Patents

Система и способ многофазного высвобождения факторов роста Download PDF

Info

Publication number
RU2633057C2
RU2633057C2 RU2013150080A RU2013150080A RU2633057C2 RU 2633057 C2 RU2633057 C2 RU 2633057C2 RU 2013150080 A RU2013150080 A RU 2013150080A RU 2013150080 A RU2013150080 A RU 2013150080A RU 2633057 C2 RU2633057 C2 RU 2633057C2
Authority
RU
Russia
Prior art keywords
growth factor
bmp
carrier
release
growth
Prior art date
Application number
RU2013150080A
Other languages
English (en)
Russian (ru)
Other versions
RU2013150080A (ru
Inventor
Кэмерон М.Л. КЛОУКИ
Шон А.Ф. ПИЛ
Original Assignee
Индьюс Байолоджикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индьюс Байолоджикс Инк. filed Critical Индьюс Байолоджикс Инк.
Publication of RU2013150080A publication Critical patent/RU2013150080A/ru
Application granted granted Critical
Publication of RU2633057C2 publication Critical patent/RU2633057C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ceramic Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polymers & Plastics (AREA)
  • Materials For Medical Uses (AREA)
RU2013150080A 2011-04-11 2012-04-11 Система и способ многофазного высвобождения факторов роста RU2633057C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161474049P 2011-04-11 2011-04-11
US61/474,049 2011-04-11
PCT/CA2012/050234 WO2012139223A1 (en) 2011-04-11 2012-04-11 System and method for multiphasic release of growth factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017134806A Division RU2017134806A (ru) 2011-04-11 2012-04-11 Система и способ многофазного высвобождения факторов роста

Publications (2)

Publication Number Publication Date
RU2013150080A RU2013150080A (ru) 2015-05-20
RU2633057C2 true RU2633057C2 (ru) 2017-10-11

Family

ID=47008753

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013150080A RU2633057C2 (ru) 2011-04-11 2012-04-11 Система и способ многофазного высвобождения факторов роста
RU2017134806A RU2017134806A (ru) 2011-04-11 2012-04-11 Система и способ многофазного высвобождения факторов роста

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017134806A RU2017134806A (ru) 2011-04-11 2012-04-11 Система и способ многофазного высвобождения факторов роста

Country Status (11)

Country Link
US (5) US9675670B2 (https=)
EP (1) EP2696852B1 (https=)
JP (1) JP6224579B2 (https=)
CN (1) CN103596553B (https=)
AU (2) AU2012243410B8 (https=)
BR (2) BR112013026241A2 (https=)
CA (1) CA2833023C (https=)
DK (1) DK2836195T3 (https=)
RU (2) RU2633057C2 (https=)
WO (1) WO2012139223A1 (https=)
ZA (1) ZA201307453B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665155C1 (ru) * 2018-01-10 2018-08-28 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ доставки биологически активных веществ в скаффолд
RU2789807C1 (ru) * 2022-06-03 2023-02-10 Федеральное государственное бюджетное учреждение науки Институт физики твердого тела имени Ю.А. Осипьяна Российской академии наук (ИФТТ РАН) Способ таргетной доставки терапевтических препаратов к опухолевым клеткам

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011820A (es) * 2013-03-14 2016-01-25 Genzyme Corp Composiciones termosensibles para crecimiento oseo.
HUE068789T2 (hu) * 2014-03-14 2025-01-28 Univ New York State Res Found A csontnövekedés és a csontlebontás neurogén szabályozása
CN104894069B (zh) * 2015-05-07 2019-07-12 中国人民解放军第四军医大学 一种光控胰岛素节律性分泌的组织工程装置
CN107412859B (zh) * 2017-04-26 2020-07-14 温州医科大学附属口腔医院 一种双基因时序性缓释的组织工程支架材料的制备方法
CN109568670B (zh) * 2018-10-24 2021-05-07 温州医科大学 一种子宫内膜损伤修复的水凝胶及其制备方法
MA54618A (fr) * 2018-12-25 2021-11-03 Orthorebirth Co Ltd Matériau de régénération osseuse ayant une structure de type ouate formée d'une pluralité de fibres électrofilées
WO2020232436A1 (en) 2019-05-16 2020-11-19 Brown University A human in vitro cardiotoxicity model
GB202106973D0 (en) * 2021-05-14 2021-06-30 Locate Bio Ltd Osteoconductive implant material with BMP-2 delivery
US12076437B2 (en) 2021-07-12 2024-09-03 Brown University Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177785C2 (ru) * 1994-08-04 2002-01-10 Квадрант Холдингс Кембридж Лимитед Твердые системы доставки для контролируемого высвобождения включенных в них молекул и способы их приготовления
WO2006093808A1 (en) * 2005-02-25 2006-09-08 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
WO2010000061A1 (en) * 2008-07-03 2010-01-07 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
US20100021518A1 (en) * 2008-07-23 2010-01-28 Warsaw Orthopedic, Inc. Foam carrier for bone grafting

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4789732A (en) 1980-08-04 1988-12-06 Regents Of The University Of California Bone morphogenetic protein composition
US4795804A (en) 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4857456A (en) 1985-04-30 1989-08-15 The Regents Of The University Of California Assay of Bone morphogenetic protein (BMP) and anti-BMP antibody for the diagnosis of bone disorders
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US5631142A (en) 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
EP0957943B2 (en) 1997-02-07 2008-11-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
CA2360938C (en) 1999-02-02 2008-01-08 Warren Oliver Haggard Controlled release composite
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US20070190102A1 (en) 2000-06-30 2007-08-16 Ping Luo Method of preparing hydroxyapatite based drug delivery implant for infection and cancer treatment
US6503109B1 (en) 2000-07-19 2003-01-07 Marshall D. Duffield Swivel drive assembly
US20080233165A1 (en) 2000-08-07 2008-09-25 Biolok International, Inc. Time release calcium sulfate and growth factor matrix for bone augmentation
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
CN1267590C (zh) * 2004-06-11 2006-08-02 清华大学 一种用于组织修复的生长因子缓释体系的制备方法
US7325262B2 (en) 2005-03-02 2008-02-05 Standard Textile Co., Inc. Bedding hem with associated interlining
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
CN1733311A (zh) * 2005-08-18 2006-02-15 同济大学 一种包裹药物或生长因子的纳米纤维的制备方法
US20070248675A1 (en) 2005-09-08 2007-10-25 Gwangju Institute Of Science And Technology Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof
US20070255422A1 (en) 2006-04-25 2007-11-01 Mei Wei Calcium phosphate polymer composite and method
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
WO2010017288A1 (en) 2008-08-05 2010-02-11 The University Of Miami Composite bone grafts, particulate bone-calcium sulfate constructs, and methods of treating joint injuries
US20110027331A1 (en) * 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2177785C2 (ru) * 1994-08-04 2002-01-10 Квадрант Холдингс Кембридж Лимитед Твердые системы доставки для контролируемого высвобождения включенных в них молекул и способы их приготовления
WO2006093808A1 (en) * 2005-02-25 2006-09-08 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
WO2010000061A1 (en) * 2008-07-03 2010-01-07 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
US20100021518A1 (en) * 2008-07-23 2010-01-28 Warsaw Orthopedic, Inc. Foam carrier for bone grafting

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2665155C1 (ru) * 2018-01-10 2018-08-28 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ доставки биологически активных веществ в скаффолд
RU2789807C1 (ru) * 2022-06-03 2023-02-10 Федеральное государственное бюджетное учреждение науки Институт физики твердого тела имени Ю.А. Осипьяна Российской академии наук (ИФТТ РАН) Способ таргетной доставки терапевтических препаратов к опухолевым клеткам

Also Published As

Publication number Publication date
CN103596553A (zh) 2014-02-19
CA2833023C (en) 2020-07-21
US20190117734A1 (en) 2019-04-25
CA2833023A1 (en) 2012-10-18
AU2017200773A1 (en) 2017-03-02
JP6224579B2 (ja) 2017-11-01
BR112014024968A2 (pt) 2017-07-11
US9675670B2 (en) 2017-06-13
US20140100161A1 (en) 2014-04-10
DK2836195T3 (da) 2021-05-25
US20170340707A1 (en) 2017-11-30
US20150196620A1 (en) 2015-07-16
US20170266259A1 (en) 2017-09-21
US9724389B2 (en) 2017-08-08
AU2012243410B2 (en) 2016-11-03
ZA201307453B (en) 2019-11-27
AU2012243410B8 (en) 2016-11-17
EP2696852A1 (en) 2014-02-19
AU2012243410A1 (en) 2013-05-09
BR112013026241A2 (pt) 2019-09-24
RU2017134806A (ru) 2019-02-07
CN103596553B (zh) 2019-01-08
JP2014510763A (ja) 2014-05-01
BR112014024968B1 (pt) 2022-11-29
WO2012139223A1 (en) 2012-10-18
RU2013150080A (ru) 2015-05-20
EP2696852A4 (en) 2014-09-24
EP2696852B1 (en) 2018-06-06
AU2012243410A8 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
RU2633057C2 (ru) Система и способ многофазного высвобождения факторов роста
Woo et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix
EP0616814A1 (en) Compositions for controlled release of biologically active TGF - beta
US20090162436A1 (en) Compositions and methods for repair of tissues
JP2009541358A (ja) 骨形成を強化するためにｂｍｐ−２増幅因子／共活性化因子を送達するための組成物および方法
Kossover et al. Growth factor delivery for the repair of a critical size tibia defect using an acellular, biodegradable polyethylene glycol–albumin hydrogel implant
AU2012376780B2 (en) System and method for multiphasic release of growth factors
US20110182911A1 (en) Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
Johnson Delivery of BMP-2 for bone tissue engineering applications
Han Effects of human hair keratin alkylation on growth factor delivery and cellular response: implications in bone regeneration
Li Biodegradable polyurethane scaffolds and delivery systems for regeneration of bone tissue

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180412